Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB099280 in advanced solid tumors
NCT04242199Phase 1Completed
- Sponsor
- Incyte
- Start
- Sep 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of incb099280 in solid tumor, microsatellite instability-high cancer, cutaneous squamous cell carcinoma (cSCC) and 8 more (3 cohorts), sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events at 25 months. Started Sep 2020; status: completed.
02
Drugs
incb099280
03
Conditions
solid tumormicrosatellite instability-high cancercutaneous squamous cell carcinoma (cSCC)urothelial carcinoma (UC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04242199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242199.